When a prediction market startup files for a stock index futures product, the exchange establishment doesn’t just roll over—it sues. On August 18, 2025, Kalshi, the CFTC-regulated exchange that began as a platform for betting on election outcomes, submitted an application to list perpetual futures on a US large-cap stock index. The reaction from the incumbents was immediate: CME Group filed a lawsuit against the CFTC, challenging the very regulatory approval that allowed Kalshi to launch crypto perpetuals just months earlier. This is not a story about technology. It’s a story about regulatory turf, product mechanics, and the quiet war between speed and scale.
Tracing the alpha from the prediction market to the perpetual.
Kalshi’s trajectory is a masterclass in regulatory arbitrage wrapped in a product innovation. Launched in 2018 as a prediction market platform, it gradually acquired the licenses to operate as a designated contract market (DCM) under the Commodity Exchange Act. In May 2025, the CFTC approved its first crypto perpetual futures—a 24/7, no-expiry contract on Bitcoin and Ethereum. Within a week of the June launch, Kalshi reported a staggering $1 billion in notional trading volume. Then, in rapid succession, it filed for perpetuals on gold, silver, copper, and finally, a stock index tracking the MerQube US Large Cap Index. The speed is dizzying. The market is now asking: Is this a legitimate threat to the CME duopoly, or a regulatory flash in the pan?
Deconstructing the terraformed logic of regulatory approval.
From a technical standpoint, Kalshi’s product is not a breakthrough. The perpetual futures mechanism—no expiration date, funding rate to anchor the contract price to the spot index—was pioneered by BitMEX in 2016 and later refined by Binance, dYdX, and others. What Kalshi has done is transplant this mechanism from the unregulated crypto world into the heavily regulated US derivatives market. The index data comes from MerQube, a third-party provider. The trading engine is a centralized order book, not a smart contract. There is no blockchain involved in the settlement or custody. The innovation is purely in the product wrapper: a regulated, 24/7, no-expiry derivative that competes directly with CME’s micro E-mini futures, which expire quarterly and trade only during pit hours.
From my own experience modeling the liquidity spillover effects of the Bitcoin ETF approvals in early 2024, I’ve seen how a new product can attract retail flow that was previously locked out. The key variable is the funding rate mechanism. In a perpetual contract, traders pay each other based on the difference between the contract price and the spot index. If the contract trades at a premium, longs pay shorts; if at a discount, shorts pay longs. This creates a self-correcting mechanism that keeps the price anchored. But the stability of this mechanism depends on continuous, accurate index data. Kalshi’s reliance on MerQube introduces a single point of failure. If the data feed is interrupted or the licensing agreement is terminated, the contract could be forced into a manual pricing mode or halted entirely. This is a risk that the market has not yet priced in.
Core: The volume numbers and the hidden asymmetry.
The $1 billion notional volume in the first week of crypto perpetuals is impressive, but it’s a single data point. Without disclosure of average daily volume, open interest, or the number of active traders, it’s impossible to know if this is a structural trend or a launch-day pump. Kalshi’s own press release cites a 2025 industry projection that global perpetual futures trading volume will exceed $90 trillion annually. Even a fraction of that would be transformative for a startup. But the projection is from a third-party firm that likely uses a broad definition of “perpetual” that includes unregulated offshore exchanges. The real addressable market for a regulated US product is much smaller.
Chasing the narrative before the chart confirms.
Now, the contrarian angle: the market is underestimating the regulatory risk, and the incumbents are overreacting in a way that could backfire. CME’s lawsuit against the CFTC is a defensive move, but it also signals that the traditional exchanges see Kalshi as a genuine threat. The lawsuit’s core argument is likely that the CFTC exceeded its authority by approving a product that falls under the “exclusive” jurisdiction of existing futures exchanges. If the court rules in favor of CME, it could not only block the stock index perpetual but also revoke the crypto perpetual approval. That would be a catastrophic binary event for Kalshi. Yet, the market reaction was muted. CME and Cboe shares rose by 1.26% and 0.12% respectively on the day of the filing. Investors are treating the lawsuit as noise, not a signal. This is a classic example of “Regulatory whispers, market shouts” — the opposite case. The whispers are loud, but the market is shouting indifference.
Speed is the only moat in noise.
But let’s step back. Kalshi’s real advantage is not technology or even regulatory approval—it’s speed. The company filed for gold, silver, and copper perpetuals within weeks of the crypto launch. The stock index application followed a month later. It is moving faster than the incumbents can react. CME has the liquidity, the institutional trust, and the network effects, but it lacks the agility to launch a 24/7 no-expiry product without cannibalizing its existing quarterly futures. Kalshi is targeting the retail and semi-professional trader who wants to hold a position overnight without worrying about rollover costs. This is a niche, but a potentially large one.
From my own analysis of the Terra collapse in 2022, I learned that the most dangerous narratives are the ones that are partially true. Kalshi’s story is compelling: a regulated platform bringing crypto-native mechanics to traditional assets. But the same mechanism that makes perpetuals attractive—the funding rate—also creates a structural vulnerability. In a low-volatility environment for stock indices, the funding rate may not generate enough incentive for arbitrageurs to keep the price anchored. The contract could drift away from the spot index, leading to dislocations and loss of trader confidence. I have seen this happen in thinly traded perpetuals on smaller exchanges.
Takeaway: The next watch is not the product—it’s the court docket.
The CFTC has a history of approving innovative products, but it also has a history of reversing course under political pressure. The CME lawsuit adds a layer of legal uncertainty that could drag on for months. If the court grants a preliminary injunction, Kalshi’s stock index perpetual application could be frozen indefinitely. If the court dismisses the case, the floodgates open—not just for Kalshi, but for every other platform that wants to list regulated perpetuals. The real battle is not between Kalshi and CME. It is between two visions of the derivatives market: one that is fast, retail-friendly, and 24/7, and another that is slow, institutional, and bound by tradition. The market thinks the outcome is already priced in. I am not so sure.
In the end, Kalshi’s story is a test of whether regulatory speed can outrun entrenched incumbents. The $1 billion volume is a proof of concept, but the real proof will come when the court decides who owns the right to create a perpetual index future. Will the Cheetah outrun the legal bear trap? The next docket entry will tell us.